October 31, 2017
Novartis waits second indication Kymriah to reach more patients
Novartis said on Tuesday that it has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novartis
October 30, 2017
Novartis expands its oncology arm with AAA
Novartis said on Monday that it wants to buy Advanced Accelerator Applications (AAA), a radiopharmaceutical company that owns and sells…
October 27, 2017
Sandoz is seeking approval for use of its biosimilar to Amgen’s Neulasta, EMA to take a look at it
Novartis division Sandoz has gotten acceptance for its biosimilar to Amgen’s Neulasta by the European Medicines Agency (EMA) for regulatory…
October 24, 2017
Novartis divisions in Q3 push income up 10%
Novartis said on Tuesday that its net sales were up 2% with growth in all divisions, which made net income…
October 18, 2017
Novartis with positive results for Revolade for chronic/persistent immune thrombocytopenia (ITP)
Novartis on Wednesday announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic immune…
October 2, 2017
Novartis’s Alcon introduces new innovations in cataract surgery at ESCRS 2017 annual congress
Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.
September 28, 2017
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”
September 22, 2017
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis has enterned in new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers.
September 20, 2017
EC approves Novartis’s cancer drug for 2 indications
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…
September 14, 2017
Novartis’s adalimumab offers alternative for patients with immunological diseases
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.